BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids. 2020;20:480-490. [PMID: 32278307 DOI: 10.1016/j.omtn.2020.03.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Lv W, Li T, Wang S, Wang H, Li X, Zhang S, Wang L, Xu Y, Wei W. The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer. Technol Cancer Res Treat 2021;20:15330338211045206. [PMID: 34605326 DOI: 10.1177/15330338211045206] [Reference Citation Analysis]
2 Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol 2022; 28(14): 1405-1429 [DOI: 10.3748/wjg.v28.i14.1405] [Reference Citation Analysis]
3 Martinez MG, Combe E, Inchauspe A, Mangeot PE, Delberghe E, Chapus F, Neveu G, Alam A, Carter K, Testoni B, Zoulim F. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio 2022;:e0288821. [PMID: 35389262 DOI: 10.1128/mbio.02888-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kirby EN, Shue B, Thomas PQ, Beard MR. CRISPR Tackles Emerging Viral Pathogens. Viruses 2021;13:2157. [PMID: 34834963 DOI: 10.3390/v13112157] [Reference Citation Analysis]
5 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chen YC. CRISPR based genome editing and removal of human viruses. Prog Mol Biol Transl Sci 2021;179:93-116. [PMID: 33785179 DOI: 10.1016/bs.pmbts.2020.12.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Baddeley HJE, Isalan M. The Application of CRISPR/Cas Systems for Antiviral Therapy. Front Genome Ed 2021;3:745559. [PMID: 34723245 DOI: 10.3389/fgeed.2021.745559] [Reference Citation Analysis]
8 Kim TH, Lee SW. Therapeutic Application of Genome Editing Technologies in Viral Diseases. Int J Mol Sci 2022;23:5399. [PMID: 35628210 DOI: 10.3390/ijms23105399] [Reference Citation Analysis]
9 Jacobs R, Singh P, Smith T, Arbuthnot P, Maepa MB. Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases. Gene Ther 2022. [PMID: 35606493 DOI: 10.1038/s41434-022-00342-5] [Reference Citation Analysis]
10 Garcia-Garcia S, Cortese MF, Rodríguez-Algarra F, Tabernero D, Rando-Segura A, Quer J, Buti M, Rodríguez-Frías F. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. Expert Rev Mol Diagn 2021;21:381-96. [PMID: 33880971 DOI: 10.1080/14737159.2021.1913055] [Reference Citation Analysis]
11 Batskikh S, Morozov S, Vinnitskaya E, Sbikina E, Borunova Z, Dorofeev A, Sandler Y, Saliev K, Kostyushev D, Brezgin S, Kostyusheva A, Chulanov V. May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases? Adv Ther 2022;39:430-40. [PMID: 34762287 DOI: 10.1007/s12325-021-01983-5] [Reference Citation Analysis]
12 Wang D, Chen L, Li C, Long Q, Yang Q, Huang A, Tang H. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy. J Nanobiotechnology 2022;20:27. [PMID: 34991617 DOI: 10.1186/s12951-021-01233-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kim J, Kwon H, Kalsoom F, Sajjad MA, Lee HW, Lim JH, Jung J, Chwae Y, Park S, Shin H, Kim K. Ca2+/Calmodulin-Dependent Protein Kinase II Inhibits Hepatitis B Virus Replication from cccDNA via AMPK Activation and AKT/mTOR Suppression. Microorganisms 2022;10:498. [DOI: 10.3390/microorganisms10030498] [Reference Citation Analysis]
14 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Luthra R, Kaur S, Bhandari K. Applications of CRISPR as a potential therapeutic. Life Sci 2021;284:119908. [PMID: 34453943 DOI: 10.1016/j.lfs.2021.119908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ghosh S, Chakraborty A, Banerjee S. Persistence of Hepatitis B Virus Infection: A Multi-Faceted Player for Hepatocarcinogenesis. Front Microbiol 2021;12:678537. [PMID: 34526974 DOI: 10.3389/fmicb.2021.678537] [Reference Citation Analysis]
17 Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;8:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
18 Goh ZY, Ren EC, Ko HL. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. World J Gastroenterol 2021; 27(14): 1369-1391 [PMID: 33911462 DOI: 10.3748/wjg.v27.i14.1369] [Reference Citation Analysis]
19 Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol 2022; 11(1): 57-72 [DOI: 10.5501/wjv.v11.i1.57] [Reference Citation Analysis]
20 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
21 González Castro N, Bjelic J, Malhotra G, Huang C, Alsaffar SH. Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. Int J Mol Sci 2021;22:10355. [PMID: 34638696 DOI: 10.3390/ijms221910355] [Reference Citation Analysis]
22 Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol 2021;75:706-17. [PMID: 34051332 DOI: 10.1016/j.jhep.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F. Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100480] [Reference Citation Analysis]
24 Jamehdor S, Pajouhanfar S, Saba S, Uzan G, Teimoori A, Naserian S. Principles and Applications of CRISPR Toolkit in Virus Manipulation, Diagnosis, and Virus-Host Interactions. Cells 2022;11:999. [PMID: 35326449 DOI: 10.3390/cells11060999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shojaei Baghini S, Gardanova ZR, Abadi SAH, Zaman BA, İlhan A, Shomali N, Adili A, Moghaddar R, Yaseri AF. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cell Mol Biol Lett 2022;27:35. [PMID: 35508982 DOI: 10.1186/s11658-022-00336-6] [Reference Citation Analysis]
26 Teng M, Yao Y, Nair V, Luo J. Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development. Viruses 2021;13:779. [PMID: 33924851 DOI: 10.3390/v13050779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Zhen S, Qiang R, Lu J, Tuo X, Yang X, Li X. Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA/cas9 produces a synergistic antiviral effect in HBV infection. Mol Immunol 2021;130:7-13. [PMID: 33340931 DOI: 10.1016/j.molimm.2020.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14:657. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Singh P, Kairuz D, Arbuthnot P, Bloom K. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol 2021; 27(23): 3182-3207 [PMID: 34163105 DOI: 10.3748/wjg.v27.i23.3182] [Reference Citation Analysis]
30 Kostyushev D, Kostyusheva A, Ponomareva N, Brezgin S, Chulanov V. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. Nucleic Acid Ther 2021. [PMID: 34797701 DOI: 10.1089/nat.2021.0075] [Reference Citation Analysis]
31 Tang N, Zhang Y, Shen Z, Yao Y, Nair V. Application of CRISPR-Cas9 Editing for Virus Engineering and the Development of Recombinant Viral Vaccines. CRISPR J 2021;4:477-90. [PMID: 34406035 DOI: 10.1089/crispr.2021.0017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Dandri M, Petersen J. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Infect Drug Resist 2020;13:3873-86. [PMID: 33149632 DOI: 10.2147/IDR.S240472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]